Cumulative exposure to estrogen may increase the risk of migraine in women.

IF 5 2区医学 Q1 CLINICAL NEUROLOGY

Cephalalgia Pub Date : 2024-01-01 DOI:10.1177/03331024231225972

Nora Stensland Bugge, Kjersti Grøtta Vetvik, Karl Bjørnar Alstadhaug, Tonje Braaten

{"title":"Cumulative exposure to estrogen may increase the risk of migraine in women.","authors":"Nora Stensland Bugge, Kjersti Grøtta Vetvik, Karl Bjørnar Alstadhaug, Tonje Braaten","doi":"10.1177/03331024231225972","DOIUrl":null,"url":null,"abstract":"Background: Migraine is a common disorder, particularly affecting women during their reproductive years. This female preponderance has been linked to exposure to female sex hormones.Methods: We used self-reported data from women born in 1943-1965 enrolled in the Norwegian Women and Cancer Study to examine the differences between women with migraine and women without migraine in a prospective design with respect to both endogenous and exogenous female sex hormone exposure.Results: In total, 62,959 women were included in the study, of whom 24.8% reported previous migraine (n = 15,635). Using a Cox proportional hazards model, we found that higher age at menarche reduced the risk of migraine (hazards ratio (HR) = 0.96, 95% confidence interval (CI) = 0.95-0.98) and that oral contraceptive use and parity increased the risk of migraine (HR = 1.12, 95% CI = 1.06-1.18 and HR = 1.37, 95% CI = 1.29-1.46, respectively).Conclusions: Older age at menarche appears to reduce migraine risk, whereas oral contraceptive use and having children appear to increase the risk. Further research is required to investigate the causality of these associations.","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":null,"pages":null},"PeriodicalIF":5.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cephalalgia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03331024231225972","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Migraine is a common disorder, particularly affecting women during their reproductive years. This female preponderance has been linked to exposure to female sex hormones.

Methods: We used self-reported data from women born in 1943-1965 enrolled in the Norwegian Women and Cancer Study to examine the differences between women with migraine and women without migraine in a prospective design with respect to both endogenous and exogenous female sex hormone exposure.

Results: In total, 62,959 women were included in the study, of whom 24.8% reported previous migraine (n = 15,635). Using a Cox proportional hazards model, we found that higher age at menarche reduced the risk of migraine (hazards ratio (HR) = 0.96, 95% confidence interval (CI) = 0.95-0.98) and that oral contraceptive use and parity increased the risk of migraine (HR = 1.12, 95% CI = 1.06-1.18 and HR = 1.37, 95% CI = 1.29-1.46, respectively).

Conclusions: Older age at menarche appears to reduce migraine risk, whereas oral contraceptive use and having children appear to increase the risk. Further research is required to investigate the causality of these associations.

查看原文本刊更多论文

累积接触雌激素可能会增加女性偏头痛的风险。

背景：偏头痛是一种常见疾病，尤其影响育龄期女性。这种女性居多的现象与接触女性性激素有关：我们利用挪威妇女与癌症研究（Norwegian Women and Cancer Study）中1943-1965年出生妇女的自我报告数据，在前瞻性设计中研究了偏头痛妇女与非偏头痛妇女在内源性和外源性女性性激素暴露方面的差异：共有62959名女性参与了这项研究，其中24.8%的女性报告曾患有偏头痛（n = 15635）。通过使用 Cox 比例危险模型，我们发现初潮年龄越大，偏头痛的风险越低（危险比 (HR) = 0.96，95% 置信区间 (CI) = 0.95-0.98），而口服避孕药和奇偶校验会增加偏头痛的风险（HR = 1.12，95% CI = 1.06-1.18 和 HR = 1.37，95% CI = 1.29-1.46）：结论：初潮年龄越大，偏头痛的风险越低，而口服避孕药和生育则会增加偏头痛的风险。需要进一步研究这些关联的因果关系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cephalalgia 医学-临床神经学

CiteScore

10.10

自引率

6.10%

发文量

108

审稿时长

4-8 weeks

期刊介绍： Cephalalgia contains original peer reviewed papers on all aspects of headache. The journal provides an international forum for original research papers, review articles and short communications. Published monthly on behalf of the International Headache Society, Cephalalgia''s rapid review averages 5 ½ weeks from author submission to first decision.